Nanobiotix (NBTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Nanobiotix stock (NBTX) is currently trading at $30.63. Nanobiotix PS ratio (Price-to-Sales) is 138.27. Analyst consensus price target for NBTX is $27.22. WallStSmart rates NBTX as Sell.
- NBTX PE ratio analysis and historical PE chart
- NBTX PS ratio (Price-to-Sales) history and trend
- NBTX intrinsic value — DCF, Graham Number, EPV models
- NBTX stock price prediction 2025 2026 2027 2028 2029 2030
- NBTX fair value vs current price
- NBTX insider transactions and insider buying
- Is NBTX undervalued or overvalued?
- Nanobiotix financial analysis — revenue, earnings, cash flow
- NBTX Piotroski F-Score and Altman Z-Score
- NBTX analyst price target and Smart Rating
Nanobiotix
📊 No data available
Try selecting a different time range
Smart Analysis
Nanobiotix (NBTX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Nanobiotix (NBTX) Key Strengths (1)
Revenue surging 186.80% year-over-year
Nanobiotix (NBTX) Areas to Watch (6)
Company is destroying shareholder value
Near-zero operating margins, business under pressure
Very expensive at 138.3x annual revenue
Very expensive at 65.0x book value
Very low institutional interest at 11.82%
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Nanobiotix (NBTX) Detailed Analysis Report
Overall Assessment
This company scores 21/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 186.80%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (138.27), Price/Book (65.02) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -198.70%, Operating Margin at 3.06%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -198.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 186.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NBTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NBTX's Price-to-Sales ratio of 138.27x sits near its historical average of 157.85x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 28% below its historical high of 191.14x set in Mar 2026, and 0% above its historical low of 138.27x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Nanobiotix (NBTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Nanobiotix is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 10M with 187% growth year-over-year.
Key Findings
Revenue growing at 187% YoY, reaching 10M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of -0.74 indicates a conservative balance sheet with 29M in cash.
Free cash flow is -18M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Nanobiotix maintain 187%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Nanobiotix.
Bottom Line
Nanobiotix is a high-conviction growth story with revenue accelerating at 187% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Nanobiotix(NBTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Nanobiotix SA, a clinical-stage biotechnology, is focused on the development of candidate products for the treatment of cancer. The company is headquartered in Paris, France.